

Julie C Stout

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2221111/publications.pdf>

Version: 2024-02-01

236
papers

19,339
citations

13865

67
h-index

12946

131
g-index

239
all docs

239
docs citations

239
times ranked

13097
citing authors

#	ARTICLE	IF	CITATIONS
1	Huntington disease: natural history, biomarkers and prospects for therapeutics. <i>Nature Reviews Neurology</i> , 2014, 10, 204-216.	10.1	873
2	Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. <i>Lancet Neurology</i> , The, 2009, 8, 791-801.	10.2	856
3	Effects of age on tissues and regions of the cerebrum and cerebellum. <i>Neurobiology of Aging</i> , 2001, 22, 581-594.	3.1	809
4	Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. <i>Lancet Neurology</i> , The, 2013, 12, 637-649.	10.2	704
5	Detection of Huntington's disease decades before diagnosis: the Predict-HD study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2008, 79, 874-880.	1.9	696
6	Marital quality, marital disruption, and immune function.. <i>Psychosomatic Medicine</i> , 1987, 49, 13-34.	2.0	557
7	Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. <i>Lancet Neurology</i> , The, 2011, 10, 31-42.	10.2	530
8	Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. <i>Lancet Neurology</i> , The, 2012, 11, 42-53.	10.2	479
9	Oxytocin Attenuates Amygdala Reactivity to Fear in Generalized Social Anxiety Disorder. <i>Neuropsychopharmacology</i> , 2010, 35, 2403-2413.	5.4	427
10	Corticotropin-releasing factor produces fear-enhancing and behavioral activating effects following infusion into the locus coeruleus. <i>Journal of Neuroscience</i> , 1990, 10, 176-183.	3.6	380
11	A contribution of cognitive decision models to clinical assessment: Decomposing performance on the Bechara gambling task.. <i>Psychological Assessment</i> , 2002, 14, 253-262.	1.5	368
12	Modulation of cellular immunity in medical students. <i>Journal of Behavioral Medicine</i> , 1986, 9, 5-21.	2.1	363
13	Psychiatric Symptoms in Huntington's Disease before Diagnosis: The Predict-HD Study. <i>Biological Psychiatry</i> , 2007, 62, 1341-1346.	1.3	363
14	Stress-related immune suppression: Health implications. <i>Brain, Behavior, and Immunity</i> , 1987, 1, 7-20.	4.1	352
15	Neurocognitive signs in prodromal Huntington disease.. <i>Neuropsychology</i> , 2011, 25, 1-14.	1.3	341
16	Psychosocial enhancement of immunocompetence in a geriatric population.. <i>Health Psychology</i> , 1985, 4, 25-41.	1.6	326
17	Preparing for Preventive Clinical Trials. <i>Archives of Neurology</i> , 2006, 63, 883.	4.5	292
18	Assessing Frontal Lobe Behavioral Syndromes with the Frontal Lobe Personality Scale. <i>Assessment</i> , 1999, 6, 269-284.	3.1	278

#	ARTICLE	IF	CITATIONS
19	Using Cognitive Models to Map Relations Between Neuropsychological Disorders and Human Decision-Making Deficits. <i>Psychological Science</i> , 2005, 16, 973-978.	3.3	274
20	Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study. <i>Lancet Neurology</i> , The, 2017, 16, 701-711.	10.2	248
21	Stress depresses interferon production by leukocytes concomitant with a decrease in natural killer cell activity.. <i>Behavioral Neuroscience</i> , 1986, 100, 675-678.	1.2	233
22	Stress-related impairments in cellular immunity. <i>Psychiatry Research</i> , 1985, 16, 233-239.	3.3	218
23	Neurocognitive insights into substance abuse. <i>Trends in Cognitive Sciences</i> , 2005, 9, 195-201.	7.8	205
24	A contribution of cognitive decision models to clinical assessment: Decomposing performance on the Bechara gambling task.. <i>Psychological Assessment</i> , 2002, 14, 253-262.	1.5	199
25	Clinical markers of early disease in persons near onset of Huntington's disease. <i>Neurology</i> , 2001, 57, 658-662.	1.1	197
26	Beyond disgust: impaired recognition of negative emotions prior to diagnosis in Huntington's disease. <i>Brain</i> , 2007, 130, 1732-1744.	7.6	181
27	Comparison of Decision Learning Models Using the Generalization Criterion Method. <i>Cognitive Science</i> , 2008, 32, 1376-1402.	1.7	180
28	Factor Analysis of the Frontal Systems Behavior Scale (FrSBe). <i>Assessment</i> , 2003, 10, 79-85.	3.1	179
29	Progressive Cerebral Volume Loss in Human Immunodeficiency Virus Infection. <i>Archives of Neurology</i> , 1998, 55, 161.	4.5	176
30	Cognitive mechanisms underlying risky decision-making in chronic cannabis users. <i>Journal of Mathematical Psychology</i> , 2010, 54, 28-38.	1.8	152
31	Depression and anxiety: Role of the locus coeruleus and corticotropin-releasing factor. <i>Brain Research Bulletin</i> , 1994, 35, 561-572.	3.0	149
32	Frontal Behaviors Before the Diagnosis of Huntington's Disease and Their Relationship to Markers of Disease Progression: Evidence of Early Lack of Awareness. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2010, 22, 196-207.	1.8	147
33	Cognitive modeling analysis of decision-making processes in cocaine abusers. <i>Psychonomic Bulletin and Review</i> , 2004, 11, 742-747.	2.8	138
34	Data Analytics from EnrollHD, a Global Clinical Research Platform for Huntington's Disease. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 212-224.	1.5	137
35	Motor abnormalities in premanifest persons with Huntington's disease: The PREDICT-HD study. <i>Movement Disorders</i> , 2009, 24, 1763-1772.	3.9	128
36	Stone Tool-Making and Brain Activation: Position Emission Tomography (PET) Studies. <i>Journal of Archaeological Science</i> , 2000, 27, 1215-1223.	2.4	127

#	ARTICLE	IF	CITATIONS
37	Early changes in white matter pathways of the sensorimotor cortex in premanifest Huntington's disease. <i>Human Brain Mapping</i> , 2012, 33, 203-212.	3.6	127
38	Tapping linked to function and structure in premanifest and symptomatic Huntington disease. <i>Neurology</i> , 2010, 75, 2150-2160.	1.1	124
39	Risky decision making in Huntington's disease. <i>Journal of the International Neuropsychological Society</i> , 2001, 7, 92-101.	1.8	123
40	Verbal episodic memory declines prior to diagnosis in Huntington's disease. <i>Neuropsychologia</i> , 2007, 45, 1767-1776.	1.6	122
41	Compensation in Preclinical Huntington's Disease: Evidence From the Track-On HD Study. <i>EBioMedicine</i> , 2015, 2, 1420-1429.	6.1	122
42	Verbal memory performance of patients with human immunodeficiency virus infection: Evidence of subcortical dysfunction. <i>Journal of Clinical and Experimental Neuropsychology</i> , 1994, 16, 508-523.	1.3	120
43	Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 687-694.	1.9	120
44	Stages of dysfunctional decision-making in addiction. <i>Pharmacology Biochemistry and Behavior</i> , 2018, 164, 99-105.	2.9	119
45	The cognitive burden in Huntington's disease: Pathology, phenotype, and mechanisms of compensation. <i>Movement Disorders</i> , 2014, 29, 673-683.	3.9	116
46	Saccades in presymptomatic and early stages of Huntington disease. <i>Neurology</i> , 2006, 67, 394-399.	1.1	115
47	MSH3 modifies somatic instability and disease severity in Huntington's and myotonic dystrophy type 1. <i>Brain</i> , 2019, 142, 1876-1886.	7.6	114
48	Clinical impairment in premanifest and early Huntington's disease is associated with regionally specific atrophy. <i>Human Brain Mapping</i> , 2013, 34, 519-529.	3.6	113
49	Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology</i> , 2015, 14, 39-47.	10.2	112
50	Medial frontal hyperactivity to sad faces in generalized social anxiety disorder and modulation by oxytocin. <i>International Journal of Neuropsychopharmacology</i> , 2012, 15, 883-896.	2.1	105
51	Stress depresses interferon production by leukocytes concomitant with a decrease in natural killer cell activity.. <i>Behavioral Neuroscience</i> , 1986, 100, 675-678.	1.2	103
52	Longitudinal Cognitive and Motor Changes Among Presymptomatic Huntington Disease Gene Carriers. <i>Archives of Neurology</i> , 1999, 56, 563.	4.5	99
53	Psychological Processes Underlying Risky Decisions in Drug Abusers.. <i>Psychology of Addictive Behaviors</i> , 2005, 19, 148-157.	2.1	98
54	Gut dysbiosis in Huntington's disease: associations among gut microbiota, cognitive performance and clinical outcomes. <i>Brain Communications</i> , 2020, 2, fcaa110.	3.3	98

#	ARTICLE	IF	CITATIONS
55	Motivational processes and autonomic responsivity in Asperger's disorder: Evidence from the Iowa Gambling Task. <i>Journal of the International Neuropsychological Society</i> , 2006, 12, 668-676.	1.8	97
56	Association of Dementia Severity With Cortical Gray Matter and Abnormal White Matter Volumes in Dementia of the Alzheimer Type. <i>Archives of Neurology</i> , 1996, 53, 742-749.	4.5	96
57	Selective vulnerability of Rich Club brain regions is an organizational principle of structural connectivity loss in Huntington's disease. <i>Brain</i> , 2015, 138, 3327-3344.	7.6	96
58	Longitudinal change in white matter microstructure in Huntington's disease: The IMAGE-HD study. <i>Neurobiology of Disease</i> , 2015, 74, 406-412.	4.4	89
59	Prefrontal activity in Huntington's disease reflects cognitive and neuropsychiatric disturbances: The IMAGE-HD study. <i>Experimental Neurology</i> , 2013, 239, 218-228.	4.1	85
60	White matter connectivity reflects clinical and cognitive status in Huntington's disease. <i>Neurobiology of Disease</i> , 2014, 65, 180-187.	4.4	85
61	Automated differentiation of pre-diagnosis Huntington's disease from healthy control individuals based on quadratic discriminant analysis of the basal ganglia: The IMAGE-HD study. <i>Neurobiology of Disease</i> , 2013, 51, 82-92.	4.4	80
62	Self-paced timing detects and tracks change in prodromal Huntington disease. <i>Neuropsychology</i> , 2010, 24, 435-442.	1.3	79
63	Brain Regions Showing White Matter Loss in Huntington's Disease Are Enriched for Synaptic and Metabolic Genes. <i>Biological Psychiatry</i> , 2018, 83, 456-465.	1.3	79
64	Increased cortical recruitment in Huntington's disease using a Simon task. <i>Neuropsychologia</i> , 2007, 45, 1791-1800.	1.6	77
65	Neurocognitive deficits related to poor decision making in people behind bars. <i>Psychonomic Bulletin and Review</i> , 2008, 15, 44-51.	2.8	75
66	The structural correlates of functional deficits in early huntington's disease. <i>Human Brain Mapping</i> , 2013, 34, 2141-2153.	3.6	75
67	Speech acoustic markers of early stage and prodromal Huntington's disease: A marker of disease onset?. <i>Neuropsychologia</i> , 2012, 50, 3273-3278.	1.6	74
68	Multi-Modal Neuroimaging in Premanifest and Early Huntington's Disease: 18 Month Longitudinal Data from the IMAGE-HD Study. <i>PLoS ONE</i> , 2013, 8, e74131.	2.5	74
69	HD-CAB: A cognitive assessment battery for clinical trials in Huntington's disease ^{1,2,3} . <i>Movement Disorders</i> , 2014, 29, 1281-1288.	3.9	73
70	Propensity for risk taking and trait impulsivity in the Iowa Gambling Task. <i>Personality and Individual Differences</i> , 2011, 50, 492-495.	2.9	70
71	Decline in working memory associated with HIV infection. <i>Psychological Medicine</i> , 1995, 25, 1221-1232.	4.5	69
72	Iron accumulation in the basal ganglia in Huntington's disease: cross-sectional data from the IMAGE-HD study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 545-549.	1.9	69

#	ARTICLE	IF	CITATIONS
73	Specific Psychiatric Manifestations Among Preclinical Huntington Disease Mutation Carriers. <i>Archives of Neurology</i> , 2007, 64, 116.	4.5	68
74	Hippocampal 5-HT1A Receptor and Spatial Learning and Memory. <i>Frontiers in Pharmacology</i> , 2015, 6, 289.	3.5	67
75	Movement Disorder Society Task Force Viewpoint: Huntington's Disease Diagnostic Categories. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 541-546.	1.5	67
76	Oculomotor control in asymptomatic and recently diagnosed individuals with the genetic marker for Huntington's disease. <i>Vision Research</i> , 2004, 44, 2729-2736.	1.4	66
77	Abnormal synchrony of resting state networks in premanifest and symptomatic Huntington disease: the IMAGE-HD study. <i>Journal of Psychiatry and Neuroscience</i> , 2014, 39, 87-96.	2.4	63
78	Operationalizing compensation over time in neurodegenerative disease. <i>Brain</i> , 2017, 140, 1158-1165.	7.6	62
79	Functional changes during working memory in Huntington's disease: 30-month longitudinal data from the IMAGE-HD study. <i>Brain Structure and Function</i> , 2015, 220, 501-512.	2.3	61
80	Obsessive and Compulsive Symptoms in Prediagnosed Huntington's Disease. <i>Journal of Clinical Psychiatry</i> , 2008, 69, 1758-1765.	2.2	61
81	Functional magnetic resonance imaging of working memory in Huntington's disease: Cross-sectional data from the IMAGE-HD study. <i>Human Brain Mapping</i> , 2014, 35, 1847-1864.	3.6	60
82	Strategic and non-strategic problem gamblers differ on decision-making under risk and ambiguity. <i>Addiction</i> , 2014, 109, 1128-1137.	3.3	58
83	Neurobehaviors and psychotic symptoms in Alzheimer's disease. <i>Journal of the International Neuropsychological Society</i> , 2000, 6, 815-820.	1.8	57
84	Functional and connectivity changes during working memory in Huntington's disease: 18-month longitudinal data from the IMAGE-HD study. <i>Brain and Cognition</i> , 2013, 83, 80-91.	1.8	57
85	Relationship of neuropsychological and MRI measures to age of onset of schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 1998, 98, 156-164.	4.5	56
86	The structural involvement of the cingulate cortex in premanifest and early Huntington's disease. <i>Movement Disorders</i> , 2011, 26, 1684-1690.	3.9	56
87	The impact of occipital lobe cortical thickness on cognitive task performance: An investigation in Huntington's Disease. <i>Neuropsychologia</i> , 2015, 79, 138-146.	1.6	56
88	Frontal Behavioral Syndromes in Cortical and Subcortical Dementia. <i>Assessment</i> , 1996, 3, 327-337.	3.1	55
89	Discourse Comprehension in Huntington's and Parkinson's Diseases. <i>American Journal of Speech-Language Pathology</i> , 1999, 8, 137-148.	1.8	53
90	Ten-year rate of longitudinal change in neurocognitive and motor function in prediagnosis Huntington disease. <i>Movement Disorders</i> , 2008, 23, 1830-1836.	3.9	52

#	ARTICLE	IF	CITATIONS
91	Similar processes despite divergent behavior in two commonly used measures of risky decision making. <i>Journal of Behavioral Decision Making</i> , 2009, 22, 435-454.	1.7	52
92	The Trail Making Test in prodromal Huntington disease: Contributions of disease progression to test performance. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2011, 33, 567-579.	1.3	52
93	Activation of conflicting responses in Parkinson's disease: evidence for degrading and facilitating effects on response time. <i>Neuropsychologia</i> , 2005, 43, 1033-1043.	1.6	51
94	Visuomotor integration deficits precede clinical onset in Huntington's disease. <i>Neuropsychologia</i> , 2011, 49, 264-270.	1.6	49
95	Reduced autonomic responsiveness to gambling task losses in Huntington's disease. <i>Journal of the International Neuropsychological Society</i> , 2004, 10, 239-245.	1.8	48
96	Frontal Behavioral Syndromes and Functional Status in Probable Alzheimer Disease. <i>American Journal of Geriatric Psychiatry</i> , 2003, 11, 683-686.	1.2	47
97	Individual differences in the response to forgone payoffs: an examination of high functioning drug abusers. <i>Journal of Behavioral Decision Making</i> , 2005, 18, 97-110.	1.7	46
98	Emotional face recognition deficits and medication effects in pre-manifest through stage-II Huntington's disease. <i>Psychiatry Research</i> , 2013, 207, 118-126.	3.3	45
99	Regional cerebral volume loss associated with verbal learning and memory in dementia of the Alzheimer type.. <i>Neuropsychology</i> , 1999, 13, 188-197.	1.3	44
100	Visuospatial Processing Deficits Linked to Posterior Brain Regions in Premanifest and Early Stage Huntington's Disease. <i>Journal of the International Neuropsychological Society</i> , 2016, 22, 595-608.	1.8	44
101	Association of CAG Repeats With Long-term Progression in Huntington Disease. <i>JAMA Neurology</i> , 2019, 76, 1375.	9.0	44
102	Do Patients With HIV-Associated Minor Cognitive/Motor Disorder Exhibit a "Subcortical" Memory Profile? Evidence Using the California Verbal Learning Test. <i>Assessment</i> , 1995, 2, 151-165.	3.1	43
103	Quality of Life in Huntington's Disease: A Comparative Study Investigating the Impact for those with Pre-Manifest and Early Manifest Disease, and their Partners. <i>Journal of Huntington's Disease</i> , 2013, 2, 159-175.	1.9	43
104	Multimodal imaging biomarkers in premanifest and early Huntington's disease: 30-month IMAGE-HD data. <i>British Journal of Psychiatry</i> , 2016, 208, 571-578.	2.8	43
105	Electrophysiological measures as potential biomarkers in Huntington's disease: Review and future directions. <i>Brain Research Reviews</i> , 2010, 64, 177-194.	9.0	42
106	Sequential learning models for the Wisconsin card sort task: Assessing processes in substance dependent individuals. <i>Journal of Mathematical Psychology</i> , 2010, 54, 5-13.	1.8	42
107	Computational Modeling Reveals Distinct Effects of HIV and History of Drug Use on Decision-Making Processes in Women. <i>PLoS ONE</i> , 2013, 8, e68962.	2.5	42
108	Relationships Among Apathy, Health-Related Quality of Life, and Function in Huntington's Disease. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2018, 30, 194-201.	1.8	42

#	ARTICLE	IF	CITATIONS
109	Cortisol and depression in pre-diagnosed and early stage Huntington's disease. <i>Psychoneuroendocrinology</i> , 2013, 38, 2439-2447.	2.7	40
110	HDQLIFE: development and assessment of health-related quality of life in Huntington disease (HD). <i>Quality of Life Research</i> , 2016, 25, 2441-2455.	3.1	39
111	Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS). <i>JAMA Neurology</i> , 2016, 73, 102.	9.0	38
112	Rating scales for cognition in Huntington's disease: Critique and recommendations. <i>Movement Disorders</i> , 2018, 33, 187-195.	3.9	38
113	An animal model for measuring behavioral responses to anxiogenic and anxiolytic manipulations. <i>Pharmacology Biochemistry and Behavior</i> , 1994, 47, 459-465.	2.9	37
114	Topological length of white matter connections predicts their rate of atrophy in premanifest Huntington's disease. <i>JCI Insight</i> , 2017, 2, .	5.0	37
115	Dual Task Performance in Normal Aging: A Comparison of Choice Reaction Time Tasks. <i>PLoS ONE</i> , 2013, 8, e60265.	2.5	37
116	Frontal Behavioral Syndromes and Functional Status in Probable Alzheimer Disease. <i>American Journal of Geriatric Psychiatry</i> , 2003, 11, 683-686.	1.2	36
117	Testing a longitudinal compensation model in premanifest Huntington's disease. <i>Brain</i> , 2018, 141, 2156-2166.	7.6	33
118	Beyond emotion recognition deficits: A theory guided analysis of emotion processing in Huntington's disease. <i>Neuroscience and Biobehavioral Reviews</i> , 2017, 73, 276-292.	6.1	32
119	Speech in prodromal and symptomatic Huntington's disease as a model of measuring onset and progression in dominantly inherited neurodegenerative diseases. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 107, 450-460.	6.1	32
120	Self-reported impulsivity and inhibitory control in problem gamblers. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2014, 36, 144-157.	1.3	30
121	Volumetric Analysis of the Hypothalamus in Huntington Disease Using 3T MRI: The IMAGE-HD Study. <i>PLoS ONE</i> , 2015, 10, e0117593.	2.5	30
122	Reduced amygdala volumes are related to motor and cognitive signs in Huntington's disease: The IMAGE-HD study. <i>NeuroImage: Clinical</i> , 2018, 18, 881-887.	2.7	30
123	Corpus Callosal Atrophy in Premanifest and Early Huntington's Disease. <i>Journal of Huntington's Disease</i> , 2013, 2, 517-526.	1.9	29
124	Subjective sleep problems in Huntington's disease: A pilot investigation of the relationship to brain structure, neurocognitive, and neuropsychiatric function. <i>Journal of the Neurological Sciences</i> , 2016, 364, 148-153.	0.6	29
125	Cognitive interventions to enhance neural compensation in Huntington's disease. <i>Neurodegenerative Disease Management</i> , 2015, 5, 155-164.	2.2	27
126	Longitudinal changes in the fronto-striatal network are associated with executive dysfunction and behavioral dysregulation in Huntington's disease: 30 months IMAGE-HD data. <i>Cortex</i> , 2017, 92, 139-149.	2.4	27

#	ARTICLE	IF	CITATIONS
127	An improved cognitive model of the Iowa and Soochow Gambling Tasks with regard to model fitting performance and tests of parameter consistency. <i>Frontiers in Psychology</i> , 2015, 6, 229.	2.1	26
128	Parkinson's disease alters multisensory perception: Insights from the Rubber Hand Illusion. <i>Neuropsychologia</i> , 2017, 97, 38-45.	1.6	25
129	Are Cognitive Changes Progressive in Prediagnostic HD?. <i>Cognitive and Behavioral Neurology</i> , 2007, 20, 212-218.	0.9	24
130	Computational modeling for addiction medicine. <i>Progress in Brain Research</i> , 2016, 224, 53-65.	1.4	24
131	Magnetization Transfer Imaging in Premanifest and Manifest Huntington Disease. <i>American Journal of Neuroradiology</i> , 2012, 33, 884-889.	2.4	23
132	Cross-sectional and longitudinal voxel-based grey matter asymmetries in Huntington's disease. <i>NeuroImage: Clinical</i> , 2018, 17, 312-324.	2.7	23
133	Oxytocin selectively modulates brain processing of disgust in Huntington's disease gene carriers. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 81, 11-16.	4.8	23
134	Enhanced negative priming in Parkinson's disease.. <i>Neuropsychology</i> , 2002, 16, 242-250.	1.3	21
135	Emotion Recognition Correlates With Social-Neuropsychiatric Dysfunction in Huntington's Disease. <i>Journal of the International Neuropsychological Society</i> , 2018, 24, 417-423.	1.8	21
136	Apathy predicts rate of cognitive decline over 24 months in premanifest Huntington's disease. <i>Psychological Medicine</i> , 2021, 51, 1338-1344.	4.5	21
137	Comparing the Iowa and Soochow Gambling Tasks in Opiate Users. <i>Frontiers in Neuroscience</i> , 2012, 6, 34.	2.8	20
138	Pilot Validation of Ambulatory Activity Monitors for Sleep Measurement in Huntington's Disease Gene Carriers. <i>Journal of Huntington's Disease</i> , 2017, 6, 249-253.	1.9	20
139	Visual perception in prediagnostic and early stage Huntington's disease. <i>Journal of the International Neuropsychological Society</i> , 2008, 14, 446-453.	1.8	19
140	The relationship between cortisol and verbal memory in the early stages of Huntington's disease. <i>Journal of Neurology</i> , 2013, 260, 891-902.	3.6	19
141	Magnetization Transfer Imaging in Premanifest and Manifest Huntington Disease: A 2-Year Follow-Up. <i>American Journal of Neuroradiology</i> , 2013, 34, 317-322.	2.4	19
142	Regional cerebral volume loss associated with verbal learning and memory in dementia of the Alzheimer type.. <i>Neuropsychology</i> , 1999, 13, 188-197.	1.3	19
143	Cognitive impairment and dementia in basal ganglia disorders. <i>Current Neurology and Neuroscience Reports</i> , 2005, 5, 355-363.	4.2	18
144	The loudness dependence auditory evoked potential is insensitive to acute changes in serotonergic and noradrenergic neurotransmission. <i>Human Psychopharmacology</i> , 2010, 25, 423-427.	1.5	18

#	ARTICLE	IF	CITATIONS
145	Evidence for sex differences in the loudness dependence of the auditory evoked potential in humans. <i>Human Psychopharmacology</i> , 2011, 26, 172-176.	1.5	18
146	Cognitive assessment strategies in Huntington's disease research. <i>Journal of Neuroscience Methods</i> , 2016, 265, 19-24.	2.5	18
147	Reduced Willingness to Expend Effort for Reward in Obesity: Link to Adherence to a 3â€Month Weight Loss Intervention. <i>Obesity</i> , 2017, 25, 1676-1681.	3.0	17
148	Validation of Neuro-QoL and PROMIS Mental Health Patient Reported Outcome Measures in Persons with Huntington Disease. <i>Journal of Huntington's Disease</i> , 2019, 8, 467-482.	1.9	17
149	Spatial memory in Huntingtonâ€™s disease: A comparative review of human and animal data. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 98, 194-207.	6.1	17
150	Feasibility and Efficacy of Brief Computerized Training to Improve Emotion Recognition in Premanifest and Early-Symptomatic Huntingtonâ€™s Disease. <i>Journal of the International Neuropsychological Society</i> , 2017, 23, 314-321.	1.8	16
151	Dissociable Motivational Deficits in Pre-manifest Huntingtonâ€™s Disease. <i>Cell Reports Medicine</i> , 2020, 1, 100152.	6.5	16
152	Influence of Competing Distractors on Response Selection in Huntington's Disease and Parkinson's Disease. <i>Cognitive Neuropsychology</i> , 2001, 18, 643-653.	1.1	15
153	Estimating Premorbid IQ in the Prodromal Phase of a Neurodegenerative Disease. <i>Clinical Neuropsychologist</i> , 2011, 25, 757-777.	2.3	15
154	Visual Working Memory Impairment in Premanifest Gene-Carriers and Early Huntington's Disease. <i>Journal of Huntington's Disease</i> , 2012, 1, 97-106.	1.9	15
155	Optokinetic nystagmus reflects perceptual directions in the onset binocular rivalry in Parkinsonâ€™s disease. <i>PLoS ONE</i> , 2017, 12, e0173707.	2.5	15
156	Data from 617 Healthy Participants Performing the Iowa Gambling Task: A "Many Labs" Collaboration. , 2015, 3, .		15
157	Movement sequencing in Huntington disease. <i>World Journal of Biological Psychiatry</i> , 2014, 15, 459-471.	2.6	14
158	Age and task difficulty differences in dual tasking using circle tracing and serial subtraction tasks. <i>Aging Clinical and Experimental Research</i> , 2014, 26, 201-211.	2.9	13
159	Psychopathic Personality Traits and Iowa Gambling Task Performance in Incarcerated Offenders. <i>Psychiatry, Psychology and Law</i> , 2015, 22, 134-144.	1.2	13
160	Cognitive assessment in Huntington disease clinical drug trials. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2017, 144, 227-244.	1.8	13
161	Families Affected by Huntingtonâ€™s Disease Report Difficulties in Communication, Emotional Involvement, and Problem Solving. <i>Journal of Huntington's Disease</i> , 2017, 6, 169-177.	1.9	13
162	Executive impairment is associated with unawareness of neuropsychiatric symptoms in premanifest and early Huntingtonâ€™s disease.. <i>Neuropsychology</i> , 2018, 32, 958-965.	1.3	13

#	ARTICLE	IF	CITATIONS
163	Assessment of Cognitive Symptoms in Prodromal and Early Huntington Disease. PLOS Currents, 2011, 3, RRN1250.	1.4	13
164	Visual function in Huntington's disease patients and presymptomatic gene carriers. Movement Disorders, 2003, 18, 1027-1034.	3.9	12
165	Effects of task difficulty during dual-task circle tracing in Huntington's disease. Journal of Neurology, 2015, 262, 268-276.	3.6	12
166	Feasibility of use of probabilistic reversal learning and serial reaction time tasks in clinical trials of Parkinson's disease. Parkinsonism and Related Disorders, 2015, 21, 894-898.	2.2	12
167	Utility of self-report and performance-based measures of risk for predicting driving behavior in young people. Personality and Individual Differences, 2015, 86, 184-188.	2.9	12
168	Differential effects of social stress on laboratory-based decision-making are related to both impulsive personality traits and gender. Cognition and Emotion, 2015, 29, 1475-1485.	2.0	12
169	Survival End Points for Huntington Disease Trials Prior to a Motor Diagnosis. JAMA Neurology, 2017, 74, 1352.	9.0	12
170	Evaluating cognition in individuals with Huntington disease: Neuro-QoL cognitive functioning measures. Quality of Life Research, 2018, 27, 811-822.	3.1	12
171	Working Memory-Related Effective Connectivity in Huntington's Disease Patients. Frontiers in Neurology, 2018, 9, 370.	2.4	12
172	Visual scanning and cognitive performance in prediagnostic and early-stage Huntington's disease. Movement Disorders, 2009, 24, 533-540.	3.9	11
173	Concurrent Validity of The Psychopathic Personality Inventory-Revised and The Psychopathy Checklist. Criminal Justice and Behavior, 2013, 40, 802-813.	1.8	11
174	Design optimization for clinical trials in early-stage manifest Huntington's disease. Movement Disorders, 2017, 32, 1610-1619.	3.9	11
175	Real-life hippocampal-dependent spatial memory impairments in Huntington's disease. Cortex, 2019, 119, 46-60.	2.4	11
176	Multidimensional Apathy: The Utility of the Dimensional Apathy Scale in Huntington's Disease. Movement Disorders Clinical Practice, 2021, 8, 361-370.	1.5	11
177	Functional Brain Correlates of Neuropsychiatric Symptoms in Presymptomatic Huntington's Disease: The IMAGE-HD Study. Journal of Huntington's Disease, 2015, 4, 325-332.	1.9	10
178	Diminished facial EMG responses to disgusting scenes and happy and fearful faces in Huntington's disease. Cortex, 2018, 106, 185-199.	2.4	10
179	Understanding patient-reported outcome measures in Huntington disease: at what point is cognitive impairment related to poor measurement reliability?. Quality of Life Research, 2018, 27, 2541-2555.	3.1	10
180	Pervasive autobiographical memory impairments in Huntington's disease. Neuropsychologia, 2019, 127, 123-130.	1.6	10

#	ARTICLE	IF	CITATIONS
181	Feasibility and initial validation of "HD-Mobile", a smartphone application for remote self-administration of performance-based cognitive measures in Huntington's disease. <i>Journal of Neurology</i> , 2021, 268, 590-601.	3.6	10
182	Enhanced negative priming in Parkinson's disease. <i>Neuropsychology</i> , 2002, 16, 242-50.	1.3	10
183	Striatal morphology and neurocognitive dysfunction in Huntington disease: The IMAGE-HD study. <i>Psychiatry Research - Neuroimaging</i> , 2019, 291, 1-8.	1.8	9
184	Responsiveness to change over time and test-retest reliability of the PROMIS and Neuro-QoL mental health measures in persons with Huntington disease (HD). <i>Quality of Life Research</i> , 2020, 29, 3419-3439.	3.1	9
185	Accuracy of automated amygdala MRI segmentation approaches in Huntington's disease in the IMAGE-HD cohort. <i>Human Brain Mapping</i> , 2020, 41, 1875-1888.	3.6	9
186	Emotion recognition in Parkinson's disease: Static and dynamic factors.. <i>Neuropsychology</i> , 2018, 32, 230-234.	1.3	9
187	Patient-reported outcome measures in Huntington disease: Quality of life in neurological disorders (Neuro-QoL) social functioning measures.. <i>Psychological Assessment</i> , 2018, 30, 450-458.	1.5	9
188	The Potential of Composite Cognitive Scores for Tracking Progression in Huntington's Disease. <i>Journal of Huntington's Disease</i> , 2014, 3, 197-207.	1.9	8
189	Visuomotor integration deficits are common to familial and sporadic preclinical Alzheimer's disease. <i>Brain Communications</i> , 2021, 3, fcab003.	3.3	8
190	Divergent findings regarding negative priming in Parkinson's disease: A comment of Filoteo et al. (2000) and Wylie and Stout (2000).. <i>Neuropsychology</i> , 2002, 16, 251-253.	1.3	7
191	Dual task performance in Huntington's disease: A comparison of choice reaction time tasks.. <i>Neuropsychology</i> , 2015, 29, 703-712.	1.3	7
192	Decision-making in Psychopathy. <i>Psychiatry, Psychology and Law</i> , 2016, 23, 521-537.	1.2	7
193	Agreement between clinician-rated versus patient-reported outcomes in Huntington disease. <i>Journal of Neurology</i> , 2018, 265, 1443-1453.	3.6	7
194	Juvenile Huntington's disease: left behind?. <i>Lancet Neurology</i> , The, 2018, 17, 932-933.	10.2	7
195	Visual scanning of the eye region of human faces predicts emotion recognition performance in Huntington's disease.. <i>Neuropsychology</i> , 2018, 32, 356-365.	1.3	7
196	Fibromyalgia, mood disorders, cognitive test results, cognitive symptoms and quality of life in systemic lupus erythematosus. <i>Rheumatology</i> , 2022, 62, 190-199.	1.9	7
197	Regret in the context of unobtained rewards in criminal offenders. <i>Cognition and Emotion</i> , 2014, 28, 913-925.	2.0	6
198	To simulate or not? Comment on Steingroever, Wetzels, and Wagenmakers (2014).. <i>Decision</i> , 2014, 1, 184-191.	0.5	6

#	ARTICLE	IF	CITATIONS
199	Dual Task Performance May be a Better Measure of Cognitive Processing in Huntington's Disease than Traditional Attention Tests. <i>Journal of Huntington's Disease</i> , 2015, 4, 119-130.	1.9	6
200	Deep Brain Stimulation for Parkinson's disease changes perception in the Rubber Hand Illusion. <i>Scientific Reports</i> , 2018, 8, 13842.	3.3	6
201	Apathy Associated With Impaired Recognition of Happy Facial Expressions in Huntington's Disease. <i>Journal of the International Neuropsychological Society</i> , 2019, 25, 453-461.	1.8	6
202	Utility of Huntington's Disease Assessments by Disease Stage: Floor/Ceiling Effects. <i>Frontiers in Neurology</i> , 2021, 12, 595679.	2.4	6
203	Effectiveness of gait aid prescription for improving spatiotemporal gait parameters and associated outcomes in community-dwelling older people: a systematic review. <i>Disability and Rehabilitation</i> , 2022, 44, 6139-6154.	1.8	6
204	Medication Use in Early-HD Participants in Track-HD: an Investigation of its Effects on Clinical Performance. <i>PLOS Currents</i> , 2016, 8, .	1.4	6
205	Longitudinal expression changes are weak correlates of disease progression in Huntington's disease. <i>Brain Communications</i> , 2020, 2, fcaa172.	3.3	6
206	Profiling Social Cognition in Premanifest Huntington's Disease. <i>Journal of the International Neuropsychological Society</i> , 2022, 28, 217-229.	1.8	5
207	Hippocampal and striatal volumes correlate with spatial memory impairment in Huntington's disease. <i>Journal of Neuroscience Research</i> , 2021, 99, 2948-2963.	2.9	4
208	Cognitive dysfunction in systemic lupus erythematosus: how do we advance our understanding?. <i>Lancet Rheumatology</i> , The, 2022, , .	3.9	4
209	The Lived Experiences of Depression in Huntington's Disease: A Qualitative Study. <i>Journal of Huntington's Disease</i> , 2022, 11, 321-335.	1.9	4
210	How different aspects of motor dysfunction influence day-to-day function in huntington's disease. <i>Movement Disorders</i> , 2019, 34, 1910-1914.	3.9	3
211	The Hunger Games: Homeostatic State-Dependent Fluctuations in Disinhibition Measured with a Novel Gamified Test Battery. <i>Nutrients</i> , 2021, 13, 2001.	4.1	3
212	Listener Detection of Objectively Validated Acoustic Features of Speech in Huntington's Disease. <i>Journal of Huntington's Disease</i> , 2022, 11, 71-79.	1.9	3
213	A qualitative examination of apathy and physical activity in Huntington's and Parkinson's disease. <i>Neurodegenerative Disease Management</i> , 2022, 12, 129-139.	2.2	3
214	Frontal neuropsychiatric syndromes in Huntington's disease (HD) and Parkinson's disease (PD). <i>Archives of Clinical Neuropsychology</i> , 1999, 14, 133-133.	0.5	2
215	A Game for Eliciting Trust Between People and Devices Under Diverse Performance Conditions. <i>Communications in Computer and Information Science</i> , 2018, , 172-190.	0.5	2
216	Cognitive Fitness to Drive in Huntington's Disease: Assessing the Clinical Utility of DriveSafe DriveAware. <i>Journal of Huntington's Disease</i> , 2019, 8, 87-95.	1.9	2

#	ARTICLE	IF	CITATIONS
217	F24â€¦Differences in companion and subject ratings of subjects' behaviour using the frontal systems behaviour scale (FrSBc)- findings from the track-hd study. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, A30.2-A30.	1.9	1
218	Response to <sc>T</sc>urner. Addiction, 2014, 109, 1139-1140.	3.3	1
219	Two different phenomena in basic motor speech performance in premanifest Huntington disease. Neurology, 2016, 87, 2283-2283.	1.1	1
220	Reliability and Validity of the HD-PRO-Triad™, a Health-Related Quality of Life Measure Designed to Assess the Symptom Triad of Huntingtonâ€™s Disease. Journal of Huntington's Disease, 2017, 6, 201-215.	1.9	1
221	Abnormal Visual Scanning of Emotionally Evocative Natural Scenes in Huntingtonâ€™s Disease. Frontiers in Psychology, 2017, 8, 405.	2.1	1
222	Relationship between measures of impulsivity in opioid-dependent individuals. Personality and Individual Differences, 2018, 120, 133-137.	2.9	1
223	Understanding the need for assistance with survey completion in people with Huntington disease. Quality of Life Research, 2018, 27, 801-810.	3.1	1
224	Discrete changes in the frequency and functions of autobiographical reminiscence in Huntington's disease. Memory, 2019, 27, 1345-1351.	1.7	1
225	H04â€¦The relationship of hypothalamic pituitary adrenal axis dysfunction to mood and cognitive changes in the early stages of Huntington's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, A34.3-A35.	1.9	0
226	H01â€¦Significant biological and clinical change detected over 1 year in premanifest and early stage Huntington's disease in the TRACK-HD study. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, A33.2-A33.	1.9	0
227	F04â€¦Quality of life in Huntington's disease: a comparative study investigating the impact on spouses of those with premanifest and early disease. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, A23.3-A24.	1.9	0
228	I07â€¦Image-HD: a functional magnetic resonance imaging study of spatial working memory in Huntington's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, A38.1-A38.	1.9	0
229	I06â€¦Correlations between structural damage and functional deficits in early Huntington's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, A37.2-A37.	1.9	0
230	G03â€¦Visuomotor integration deficits in premanifest and early manifest Huntington's disease in the TRACK-HD study. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, A31.3-A32.	1.9	0
231	D21â€¦Longitudinal compensation in the cognitive network in huntingtonâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A42.1-A42.	1.9	0
232	Introduction to the JINS Special Issue: Preclinical Prediction. Journal of the International Neuropsychological Society, 2016, 22, 951-955.	1.8	0
233	D20â€¦Operationalising compensation over time in neurodegenerative disease. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A41.2-A41.	1.9	0
234	D22â€¦Compensation in preclinical huntingtonâ€™s disease: evidence from the track-on HD study. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A42.2-A42.	1.9	0

#	ARTICLE	IF	CITATIONS
235	E11â€¦Compensation in huntingtonâ€™s disease. , 2018, , .		0
236	Enhancing the Clinical Utility of DriveSafe DriveAware for People with Huntingtonâ€™s Disease. Journal of Huntington's Disease, 2020, 9, 353-357.	1.9	0